You are here » Home » Companies » Company Overview » Albert David Ltd

Albert David Ltd.

BSE: 524075 Sector: Health care
NSE: ALBERTDAVD ISIN Code: INE155C01010
BSE LIVE 18:56 | 19 Oct 284.45 4.65
(1.66%)
OPEN

282.00

HIGH

284.45

LOW

279.00

NSE 19:46 | 19 Oct 283.05 3.00
(1.07%)
OPEN

287.75

HIGH

287.75

LOW

280.25

OPEN 282.00
PREVIOUS CLOSE 279.80
VOLUME 320
52-Week high 424.80
52-Week low 279.00
P/E 148.93
Mkt Cap.(Rs cr) 162
Buy Price 280.00
Buy Qty 25.00
Sell Price 284.45
Sell Qty 8.00
OPEN 282.00
CLOSE 279.80
VOLUME 320
52-Week high 424.80
52-Week low 279.00
P/E 148.93
Mkt Cap.(Rs cr) 162
Buy Price 280.00
Buy Qty 25.00
Sell Price 284.45
Sell Qty 8.00

Albert David Ltd. (ALBERTDAVD) - Chairman Speech

Company chairman speech

Albert David Ltd. is one of the stars of the highly diversified and path settingKothari Group which is based out of Kolkata.

Steady Performance

The year 2016-17 was a turbulent year both in the global as well as domestic markets. Iam pleased to report that despite these ‘un-natural' challenges we at Albert DavidLtd. have recorded a steady performance.

Dividend

Backed by the above performance the Board has proposed a dividend of 55% per equityshare of Rs.10/-.

Structural Change

In order to further strengthen our participation and performance in the IPM the Boarddecided to induct our girst CEO in Albert David Ltd. I have great pleasure in informingyou that we have appointed Mr. Tarminder Singh Parmar as the CEO of Albert David Ltd.effective 24th January'2017. Mr. Tarminder Singh Parmar is a dynamic pharma professionalhaving over 30 years of experience with leading Indian and MNC companies. He has a wideexposure across most ‘therapeutic areas' both acute and chronic and he also has arare mix of exposure across the width of multiple corporate functions. I welcome Mr. T SParmar into the Albert David Ltd. family and wish him great success on behalf of selfand on behalf of all of you.

Mr. K P Mundhra Executive Director resigned in end June'2016 after a long 46 years ofservice at Albert David Ltd. We would like to appreciate his valuable services andcontribution. Mr. H P Kabra Head Exports and Commercial Operations has been elevated asExecutive Director on the Albert David Ltd. Board from 1st July' 2016.

Future Outlook

I am confident that with the recent changes we will soon see Albert David Ltd.treading new paths and scaling greater heights. I on behalf of the Albert David Ltd.Board express my appreciation and gratitude to all our shareholders and we look forwardto your continued trust and support.

A K KOTHARI

Chairman & MD

CEO's Message

Dear Shareholders

It gives me great pleasure to address you for the first time. I joined Albert DavidLtd. on 24th January'2017 and I am excited to be associated with a company which has arich legacy has been a ‘trend-setter' in the past and has good potential lookinginto the future.

The Market Scenario

The year 2016-17 has been a ‘topsy-turvy' year having thrown multiple economicchallenges both globally as well as in India. The otherwise reasonably immune / stableIndian Pharmaceutical Market too has faced the impact having been adversely affected by acouple of developments both on the regulatory as well as economic fronts. Despite thesame we have seen the Indian economy as well as the Indian Pharmaceutical Market emergeas a ‘front-runner' on the global scene especially on the growth front. This hasbeen enabled primarily by the fundamental strength and robustness of our economy industryand systems.

Our Current Status

Albert David Ltd. is a well-established pharma company having actively operated in theIndian Pharmaceutical Market for the past many decades.

We are active across multiple ‘Therapy Areas' with greater focus in GynaecologyGI Pain and Herbal Medicines. We have been the pioneers in India particularly with ourproducts like Placentrex SSG Alamin & Herbal group of products. We have also been atthe fore-front with our wide range of IV infusions. We have recently been adding to ourproduct portfolio having launched brands in the high growth molecule segments.

Our Way Forward

The coming year will be one of consolidation as well as differentiation. We are in theprocess of an in-depth pan Corporate / pan Function review. We will identify / re-confirmour strengths and will focus on them. We are additionally doing the following:-

i) Strengthening the Systems and Processes across functions to support sustained androbust growth

ii) Identifying prioritizing and supporting the ‘Key Strategic GrowthInitiatives'

iii) Looking at additional growth opportunities especially through new products inexisting Key TAs etc.

iv) Improving our contribution from ‘exports' through advance mid / long termplanning.

I will be in a better position to give you the details of the key initiatives taken andthe benefits accrued when we review the FY 2017-18. In the meantime I can assure you thatwe in Albert David Ltd. are upgrading and updating ourselves to take ourselves towards astronger and brighter future. We surely have your support and best wishes for the same.

Yours Sincerely

T S PARMAR

Chief Executive Officer